Increased Use of Hyperosmolar Therapy for Suspected Clinically Apparent Brain Injury in Pediatric Patients with Diabetic Ketoacidosis during the Peak of the COVID-19 Pandemic

<div>Proportion of DKA cases receiving hyperosmolar therapy (mannitol or hypertonic saline) for suspected CABI over the course of the year corresponding to the peak of the COVID-19 pandemic (March 11, 2020–March 10, 2021). The data are presented in three-month intervals. CABI, clinically apparent brain injury; DKA, diabetic ketoacidosis.</div>

Pediatric Diabetes

fig1

Figure 1

Figure 1: Increased Use of Hyperosmolar Therapy for Suspected Clinically Apparent Brain Injury in Pediatric Patients with Diabetic Ketoacidosis during the Peak of the COVID-19 Pandemic 

Figure 1 | Increased Use of Hyperosmolar Therapy for Suspected Clinically Apparent Brain Injury in Pediatric Patients with Diabetic Ketoacidosis during the Peak of the COVID-19 Pandemic 